Phase 1 Liver Cancer Trial, Recruiting (NCT06044506)

Phase 1 Liver Cancer Trial, Recruiting NCT06044506 Sponsor: Dr Cipto Mangunkusumo General Hospital Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06044506 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 20 and 60 years old
You have been diagnosed with liver cancer (Hepatocellular Carcinoma) classified at a moderate to advanced stage (known as BCLC Stage B or C)
You are able to carry out most normal daily activities, as measured by a standard health scoring system (confirm with trial site)
Your doctors expect you to live for more than three months
Your blood platelet count is at an acceptable level (confirm with trial site)
Your white blood cell count is at an acceptable level (confirm with trial site)
Your neutrophil count (a type of white blood cell) is at an acceptable level (confirm with trial site)
Your hemoglobin (a measure of red blood cells) is at an acceptable level (confirm with trial site)
Your blood clotting levels are within a normal range (confirm with trial site)
Your liver is functioning well enough, based on standard blood tests (confirm with trial site)
Your kidneys are functioning well enough, based on standard blood tests (confirm with trial site)

Who may not be able to join:

You do not wish to take part in the study
You have been diagnosed with any other type of cancer, including other liver cancers that are not Hepatocellular Carcinoma
You have certain other health conditions, including high blood pressure, serious heart disease, low bone marrow activity, breathing problems, or an active or ongoing infection
You have previously had an organ transplant or received any stem cell treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Cosphiadi Irawan, MD, PhD, Cipto Mangunkusumo Hospital/Faculty of Medicine, Universitas Indonesia

Phone: +62 87870171876

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06044506

Sponsor: Dr Cipto Mangunkusumo General Hospital

Phase: Phase 1

Status: Recruiting

Condition: Liver Cancer

Trial contact: +62 87870171876

More information: https://clinicaltrials.gov/study/NCT06044506

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 20 and 60 years old
You have been diagnosed with liver cancer (Hepatocellular Carcinoma) classified at a moderate to advanced stage (known as BCLC Stage B or C)
You are able to carry out most normal daily activities, as measured by a standard health scoring system (confirm with trial site)
Your doctors expect you to live for more than three months
Your blood platelet count is at an acceptable level (confirm with trial site)
Your white blood cell count is at an acceptable level (confirm with trial site)
Your neutrophil count (a type of white blood cell) is at an acceptable level (confirm with trial site)
Your hemoglobin (a measure of red blood cells) is at an acceptable level (confirm with trial site)
Your blood clotting levels are within a normal range (confirm with trial site)
Your liver is functioning well enough, based on standard blood tests (confirm with trial site)
Your kidneys are functioning well enough, based on standard blood tests (confirm with trial site)

Who may not be able to join:

You do not wish to take part in the study
You have been diagnosed with any other type of cancer, including other liver cancers that are not Hepatocellular Carcinoma
You have certain other health conditions, including high blood pressure, serious heart disease, low bone marrow activity, breathing problems, or an active or ongoing infection
You have previously had an organ transplant or received any stem cell treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Dr Cipto Mangunkusumo General Hospital

Registry

ClinicalTrials.gov

Start date

29 August 2022

Est. completion

1 December 2026

Where this trial is recruiting

🇮🇩 Indonesia

Primary endpoints

Optimal treatment dosage

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov